#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Genetically altered mice are " superathletes "
1-1	0-11	Genetically	_	_	_	_
1-2	12-19	altered	animal[1]	new[1]	coref	1-6[0_1]
1-3	20-24	mice	animal[1]	new[1]	_	_
1-4	25-28	are	_	_	_	_
1-5	29-30	"	_	_	_	_
1-6	31-44	superathletes	animal	giv	coref	3-15[13_0]
1-7	45-46	"	_	_	_	_

#Text=Friday , November 2 , 2007
2-1	47-53	Friday	time	new	appos	2-3[5_0]
2-2	54-55	,	_	_	_	_
2-3	56-64	November	time|time[5]	new|giv[5]	_	_
2-4	65-66	2	time[5]	giv[5]	_	_
2-5	67-68	,	time[5]	giv[5]	_	_
2-6	69-73	2007	time[5]|time	giv[5]|new	_	_

#Text=Researchers at Case Western University in Cleveland , Ohio have announced the creation of transgenic mice with substantially improved athletic endurance , which live and breed longer and are more aggressive than genetically unmodified siblings , and are leaner despite consuming 60 % more food .
3-1	74-85	Researchers	person[7]	new[7]	_	_
3-2	86-88	at	person[7]	new[7]	_	_
3-3	89-93	Case	person[7]|person|organization[9]	new[7]|new|new[9]	coref	20-4[134_9]
3-4	94-101	Western	person[7]|organization[9]	new[7]|new[9]	_	_
3-5	102-112	University	person[7]|organization[9]	new[7]|new[9]	_	_
3-6	113-115	in	person[7]|organization[9]	new[7]|new[9]	_	_
3-7	116-125	Cleveland	person[7]|organization[9]|place[10]	new[7]|new[9]|new[10]	_	_
3-8	126-127	,	person[7]|organization[9]|place[10]	new[7]|new[9]|new[10]	_	_
3-9	128-132	Ohio	person[7]|organization[9]|place[10]|place	new[7]|new[9]|new[10]|new	_	_
3-10	133-137	have	_	_	_	_
3-11	138-147	announced	_	_	_	_
3-12	148-151	the	abstract[12]	new[12]	_	_
3-13	152-160	creation	abstract[12]	new[12]	_	_
3-14	161-163	of	abstract[12]	new[12]	_	_
3-15	164-174	transgenic	abstract[12]|animal[13]	new[12]|giv[13]	coref	4-1[18_13]
3-16	175-179	mice	abstract[12]|animal[13]	new[12]|giv[13]	_	_
3-17	180-184	with	abstract[12]|animal[13]	new[12]|giv[13]	_	_
3-18	185-198	substantially	abstract[12]|animal[13]|abstract[14]	new[12]|giv[13]|new[14]	coref	21-7[143_14]
3-19	199-207	improved	abstract[12]|animal[13]|abstract[14]	new[12]|giv[13]|new[14]	_	_
3-20	208-216	athletic	abstract[12]|animal[13]|abstract[14]	new[12]|giv[13]|new[14]	_	_
3-21	217-226	endurance	abstract[12]|animal[13]|abstract[14]	new[12]|giv[13]|new[14]	_	_
3-22	227-228	,	_	_	_	_
3-23	229-234	which	_	_	_	_
3-24	235-239	live	_	_	_	_
3-25	240-243	and	_	_	_	_
3-26	244-249	breed	_	_	_	_
3-27	250-256	longer	_	_	_	_
3-28	257-260	and	_	_	_	_
3-29	261-264	are	_	_	_	_
3-30	265-269	more	_	_	_	_
3-31	270-280	aggressive	_	_	_	_
3-32	281-285	than	_	_	_	_
3-33	286-297	genetically	animal[15]	new[15]	_	_
3-34	298-308	unmodified	animal[15]	new[15]	_	_
3-35	309-317	siblings	animal[15]	new[15]	_	_
3-36	318-319	,	_	_	_	_
3-37	320-323	and	_	_	_	_
3-38	324-327	are	_	_	_	_
3-39	328-334	leaner	_	_	_	_
3-40	335-342	despite	_	_	_	_
3-41	343-352	consuming	_	_	_	_
3-42	353-355	60	quantity[16]	new[16]	_	_
3-43	356-357	%	quantity[16]	new[16]	_	_
3-44	358-362	more	substance[17]	new[17]	_	_
3-45	363-367	food	substance[17]	new[17]	_	_
3-46	368-369	.	_	_	_	_

#Text=The mice have been dubbed " mighty mice " or " supermice " by the popular press and have been compared to cyclist Lance Armstrong .
4-1	370-373	The	animal[18]	giv[18]	coref	4-7[19_18]
4-2	374-378	mice	animal[18]	giv[18]	_	_
4-3	379-383	have	_	_	_	_
4-4	384-388	been	_	_	_	_
4-5	389-395	dubbed	_	_	_	_
4-6	396-397	"	_	_	_	_
4-7	398-404	mighty	animal[19]	giv[19]	coref	12-1[76_19]
4-8	405-409	mice	animal[19]	giv[19]	_	_
4-9	410-411	"	_	_	_	_
4-10	412-414	or	_	_	_	_
4-11	415-416	"	_	_	_	_
4-12	417-426	supermice	_	_	_	_
4-13	427-428	"	_	_	_	_
4-14	429-431	by	_	_	_	_
4-15	432-435	the	organization[20]	new[20]	coref	19-8[129_20]
4-16	436-443	popular	organization[20]	new[20]	_	_
4-17	444-449	press	organization[20]	new[20]	_	_
4-18	450-453	and	_	_	_	_
4-19	454-458	have	_	_	_	_
4-20	459-463	been	_	_	_	_
4-21	464-472	compared	_	_	_	_
4-22	473-475	to	_	_	_	_
4-23	476-483	cyclist	person[21]	new[21]	_	_
4-24	484-489	Lance	person[21]	new[21]	_	_
4-25	490-499	Armstrong	person[21]	new[21]	_	_
4-26	500-501	.	_	_	_	_

#Text=The changes were created by adding an extra copy of a single gene , PEPCK-C .
5-1	502-505	The	abstract[22]	new[22]	_	_
5-2	506-513	changes	abstract[22]	new[22]	_	_
5-3	514-518	were	_	_	_	_
5-4	519-526	created	_	_	_	_
5-5	527-529	by	_	_	_	_
5-6	530-536	adding	_	_	_	_
5-7	537-539	an	object[23]	new[23]	_	_
5-8	540-545	extra	object[23]	new[23]	_	_
5-9	546-550	copy	object[23]	new[23]	_	_
5-10	551-553	of	object[23]	new[23]	_	_
5-11	554-555	a	object[23]|abstract[24]	new[23]|new[24]	coref	6-1[26_24]
5-12	556-562	single	object[23]|abstract[24]	new[23]|new[24]	_	_
5-13	563-567	gene	object[23]|abstract[24]	new[23]|new[24]	_	_
5-14	568-569	,	_	_	_	_
5-15	570-577	PEPCK-C	object	new	_	_
5-16	578-579	.	_	_	_	_

#Text=This gene is already present in the mouse genome , but the modified gene is designed to be strongly active ( transcribed ) in skeletal muscle . ( The natural copy of the gene , most active in the liver , continues to function normally ) .
6-1	580-584	This	abstract[26]	giv[26]	coref	6-12[29_26]
6-2	585-589	gene	abstract[26]	giv[26]	_	_
6-3	590-592	is	_	_	_	_
6-4	593-600	already	_	_	_	_
6-5	601-608	present	_	_	_	_
6-6	609-611	in	_	_	_	_
6-7	612-615	the	abstract[28]	new[28]	coref	9-9[58_28]
6-8	616-621	mouse	animal|abstract[28]	new|new[28]	coref	9-10
6-9	622-628	genome	abstract[28]	new[28]	_	_
6-10	629-630	,	_	_	_	_
6-11	631-634	but	_	_	_	_
6-12	635-638	the	abstract[29]	giv[29]	coref	6-33[32_29]
6-13	639-647	modified	abstract[29]	giv[29]	_	_
6-14	648-652	gene	abstract[29]	giv[29]	_	_
6-15	653-655	is	_	_	_	_
6-16	656-664	designed	_	_	_	_
6-17	665-667	to	_	_	_	_
6-18	668-670	be	_	_	_	_
6-19	671-679	strongly	_	_	_	_
6-20	680-686	active	_	_	_	_
6-21	687-688	(	_	_	_	_
6-22	689-700	transcribed	_	_	_	_
6-23	701-702	)	_	_	_	_
6-24	703-705	in	_	_	_	_
6-25	706-714	skeletal	object[30]	new[30]	appos	6-29[31_30]
6-26	715-721	muscle	object[30]	new[30]	_	_
6-27	722-723	.	_	_	_	_
6-28	724-725	(	_	_	_	_
6-29	726-729	The	object[31]	giv[31]	coref	16-6[0_31]
6-30	730-737	natural	object[31]	giv[31]	_	_
6-31	738-742	copy	object[31]	giv[31]	_	_
6-32	743-745	of	object[31]	giv[31]	_	_
6-33	746-749	the	object[31]|abstract[32]	giv[31]|giv[32]	coref	7-1[34_32]
6-34	750-754	gene	object[31]|abstract[32]	giv[31]|giv[32]	_	_
6-35	755-756	,	object[31]	giv[31]	_	_
6-36	757-761	most	object[31]	giv[31]	_	_
6-37	762-768	active	object[31]	giv[31]	_	_
6-38	769-771	in	_	_	_	_
6-39	772-775	the	place[33]	new[33]	_	_
6-40	776-781	liver	place[33]	new[33]	_	_
6-41	782-783	,	_	_	_	_
6-42	784-793	continues	_	_	_	_
6-43	794-796	to	_	_	_	_
6-44	797-805	function	_	_	_	_
6-45	806-814	normally	_	_	_	_
6-46	815-816	)	_	_	_	_
6-47	817-818	.	_	_	_	_

#Text=The gene mediates a crucial rate controlling step of gluconeogenesis and glyceroneogenesis , and its activity helps to allow energy production by the mitochondrial citric acid cycle .
7-1	819-822	The	abstract[34]	giv[34]	ana	7-15[0_34]
7-2	823-827	gene	abstract[34]	giv[34]	_	_
7-3	828-836	mediates	_	_	_	_
7-4	837-838	a	abstract[35]	new[35]	_	_
7-5	839-846	crucial	abstract[35]	new[35]	_	_
7-6	847-851	rate	abstract[35]	new[35]	_	_
7-7	852-863	controlling	_	_	_	_
7-8	864-868	step	abstract[36]	new[36]	_	_
7-9	869-871	of	abstract[36]	new[36]	_	_
7-10	872-887	gluconeogenesis	abstract[36]|abstract	new[36]|new	_	_
7-11	888-891	and	abstract[36]	new[36]	_	_
7-12	892-909	glyceroneogenesis	abstract[36]|substance	new[36]|new	_	_
7-13	910-911	,	_	_	_	_
7-14	912-915	and	_	_	_	_
7-15	916-919	its	abstract|abstract[40]	giv|new[40]	coref|coref	10-1[62_0]|21-28[151_40]
7-16	920-928	activity	abstract[40]	new[40]	_	_
7-17	929-934	helps	_	_	_	_
7-18	935-937	to	_	_	_	_
7-19	938-943	allow	_	_	_	_
7-20	944-950	energy	abstract|abstract[42]	new|new[42]	coref|coref	8-5[47_0]|8-19[50_42]
7-21	951-961	production	abstract[42]	new[42]	_	_
7-22	962-964	by	_	_	_	_
7-23	965-968	the	abstract[45]	new[45]	_	_
7-24	969-982	mitochondrial	abstract[45]	new[45]	_	_
7-25	983-989	citric	abstract|abstract[45]	new|new[45]	_	_
7-26	990-994	acid	substance|abstract[45]	new|new[45]	_	_
7-27	995-1000	cycle	abstract[45]	new[45]	_	_
7-28	1001-1002	.	_	_	_	_

#Text=In the transgenics , more energy is available to muscle through the burning of fatty acids , with much less production of lactate ( a chemical that leads to sore muscles when one exercises ) .
8-1	1003-1005	In	_	_	_	_
8-2	1006-1009	the	abstract[46]	new[46]	_	_
8-3	1010-1021	transgenics	abstract[46]	new[46]	_	_
8-4	1022-1023	,	_	_	_	_
8-5	1024-1028	more	abstract[47]	giv[47]	_	_
8-6	1029-1035	energy	abstract[47]	giv[47]	_	_
8-7	1036-1038	is	_	_	_	_
8-8	1039-1048	available	_	_	_	_
8-9	1049-1051	to	_	_	_	_
8-10	1052-1058	muscle	_	_	_	_
8-11	1059-1066	through	_	_	_	_
8-12	1067-1070	the	event[48]	new[48]	_	_
8-13	1071-1078	burning	event[48]	new[48]	_	_
8-14	1079-1081	of	event[48]	new[48]	_	_
8-15	1082-1087	fatty	event[48]|substance[49]	new[48]|new[49]	_	_
8-16	1088-1093	acids	event[48]|substance[49]	new[48]|new[49]	_	_
8-17	1094-1095	,	_	_	_	_
8-18	1096-1100	with	_	_	_	_
8-19	1101-1105	much	abstract[50]	giv[50]	ana	9-1[0_50]
8-20	1106-1110	less	abstract[50]	giv[50]	_	_
8-21	1111-1121	production	abstract[50]	giv[50]	_	_
8-22	1122-1124	of	abstract[50]	giv[50]	_	_
8-23	1125-1132	lactate	abstract[50]|substance	giv[50]|new	appos	8-25[52_0]
8-24	1133-1134	(	_	_	_	_
8-25	1135-1136	a	substance[52]	giv[52]	_	_
8-26	1137-1145	chemical	substance[52]	giv[52]	_	_
8-27	1146-1150	that	_	_	_	_
8-28	1151-1156	leads	_	_	_	_
8-29	1157-1159	to	_	_	_	_
8-30	1160-1164	sore	object[53]	new[53]	_	_
8-31	1165-1172	muscles	object[53]	new[53]	_	_
8-32	1173-1177	when	_	_	_	_
8-33	1178-1181	one	abstract[54]	new[54]	_	_
8-34	1182-1191	exercises	abstract[54]	new[54]	_	_
8-35	1192-1193	)	_	_	_	_
8-36	1194-1195	.	_	_	_	_

#Text=This is not as major a change to the mouse genome as it might seem to the layperson .
9-1	1196-1200	This	abstract	giv	ana	9-13
9-2	1201-1203	is	_	_	_	_
9-3	1204-1207	not	_	_	_	_
9-4	1208-1210	as	_	_	_	_
9-5	1211-1216	major	_	_	_	_
9-6	1217-1218	a	abstract[56]	new[56]	_	_
9-7	1219-1225	change	abstract[56]	new[56]	_	_
9-8	1226-1228	to	abstract[56]	new[56]	_	_
9-9	1229-1232	the	abstract[56]|abstract[58]	new[56]|giv[58]	_	_
9-10	1233-1238	mouse	abstract[56]|animal|abstract[58]	new[56]|giv|giv[58]	coref	10-8[63_0]
9-11	1239-1245	genome	abstract[56]|abstract[58]	new[56]|giv[58]	_	_
9-12	1246-1248	as	_	_	_	_
9-13	1249-1251	it	abstract	giv	_	_
9-14	1252-1257	might	_	_	_	_
9-15	1258-1262	seem	_	_	_	_
9-16	1263-1265	to	_	_	_	_
9-17	1266-1269	the	person[60]	new[60]	_	_
9-18	1270-1279	layperson	person[60]	new[60]	_	_
9-19	1280-1281	.	_	_	_	_

#Text=The PEPCK-C gene is already present in the mouse and a variety of natural mutations could likely cause similar results .
10-1	1282-1285	The	abstract[62]	giv[62]	_	_
10-2	1286-1293	PEPCK-C	person|abstract[62]	new|giv[62]	coref	16-4[107_0]
10-3	1294-1298	gene	abstract[62]	giv[62]	_	_
10-4	1299-1301	is	_	_	_	_
10-5	1302-1309	already	_	_	_	_
10-6	1310-1317	present	_	_	_	_
10-7	1318-1320	in	_	_	_	_
10-8	1321-1324	the	animal[63]	giv[63]	coref	19-12[130_63]
10-9	1325-1330	mouse	animal[63]	giv[63]	_	_
10-10	1331-1334	and	_	_	_	_
10-11	1335-1336	a	abstract[64]	new[64]	_	_
10-12	1337-1344	variety	abstract[64]	new[64]	_	_
10-13	1345-1347	of	abstract[64]	new[64]	_	_
10-14	1348-1355	natural	abstract[64]|abstract[65]	new[64]|new[65]	_	_
10-15	1356-1365	mutations	abstract[64]|abstract[65]	new[64]|new[65]	_	_
10-16	1366-1371	could	_	_	_	_
10-17	1372-1378	likely	_	_	_	_
10-18	1379-1384	cause	_	_	_	_
10-19	1385-1392	similar	abstract[66]	new[66]	coref	18-9[120_66]
10-20	1393-1400	results	abstract[66]	new[66]	_	_
10-21	1401-1402	.	_	_	_	_

#Text=The study appears today in the Journal of Biological Chemistry in a paper with lead author Parvin Hakimi from the laboratory of Richard W. Hanson .
11-1	1403-1406	The	abstract[67]	new[67]	_	_
11-2	1407-1412	study	abstract[67]	new[67]	_	_
11-3	1413-1420	appears	_	_	_	_
11-4	1421-1426	today	time	new	_	_
11-5	1427-1429	in	_	_	_	_
11-6	1430-1433	the	organization[69]	new[69]	_	_
11-7	1434-1441	Journal	organization[69]	new[69]	_	_
11-8	1442-1444	of	organization[69]	new[69]	_	_
11-9	1445-1455	Biological	organization[69]|abstract[70]	new[69]|new[70]	_	_
11-10	1456-1465	Chemistry	organization[69]|abstract[70]	new[69]|new[70]	_	_
11-11	1466-1468	in	_	_	_	_
11-12	1469-1470	a	object[71]	new[71]	_	_
11-13	1471-1476	paper	object[71]	new[71]	_	_
11-14	1477-1481	with	_	_	_	_
11-15	1482-1486	lead	abstract|person[73]	new|new[73]	_	_
11-16	1487-1493	author	person[73]	new[73]	_	_
11-17	1494-1500	Parvin	person[73]	new[73]	_	_
11-18	1501-1507	Hakimi	person[73]	new[73]	_	_
11-19	1508-1512	from	_	_	_	_
11-20	1513-1516	the	place[74]	new[74]	_	_
11-21	1517-1527	laboratory	place[74]	new[74]	_	_
11-22	1528-1530	of	place[74]	new[74]	_	_
11-23	1531-1538	Richard	place[74]|person[75]	new[74]|new[75]	coref	18-1[0_75]
11-24	1539-1541	W.	place[74]|person[75]	new[74]|new[75]	_	_
11-25	1542-1548	Hanson	place[74]|person[75]	new[74]|new[75]	_	_
11-26	1549-1550	.	_	_	_	_

#Text=The altered mice can run at 20 meters per minute ( 0.75 miles per hour or 1.2 kilometers per hour ) for up to six kilometers ( nearly four miles ) without stopping .
12-1	1551-1554	The	animal[76]	giv[76]	coref	13-25[93_76]
12-2	1555-1562	altered	animal[76]	giv[76]	_	_
12-3	1563-1567	mice	animal[76]	giv[76]	_	_
12-4	1568-1571	can	_	_	_	_
12-5	1572-1575	run	_	_	_	_
12-6	1576-1578	at	_	_	_	_
12-7	1579-1581	20	time[77]	new[77]	_	_
12-8	1582-1588	meters	time[77]	new[77]	_	_
12-9	1589-1592	per	time[77]	new[77]	_	_
12-10	1593-1599	minute	time[77]|time	new[77]|new	coref	13-22
12-11	1600-1601	(	_	_	_	_
12-12	1602-1606	0.75	time[79]	new[79]	_	_
12-13	1607-1612	miles	time[79]	new[79]	_	_
12-14	1613-1616	per	time[79]	new[79]	_	_
12-15	1617-1621	hour	time[79]|time	new[79]|new	coref	12-20
12-16	1622-1624	or	_	_	_	_
12-17	1625-1628	1.2	quantity[81]	new[81]	_	_
12-18	1629-1639	kilometers	quantity[81]	new[81]	_	_
12-19	1640-1643	per	quantity[81]	new[81]	_	_
12-20	1644-1648	hour	quantity[81]|time	new[81]|giv	_	_
12-21	1649-1650	)	quantity[81]	new[81]	_	_
12-22	1651-1654	for	quantity[81]	new[81]	_	_
12-23	1655-1657	up	quantity[81]	new[81]	_	_
12-24	1658-1660	to	quantity[81]	new[81]	_	_
12-25	1661-1664	six	quantity[81]|quantity[83]	new[81]|new[83]	_	_
12-26	1665-1675	kilometers	quantity[81]|quantity[83]	new[81]|new[83]	_	_
12-27	1676-1677	(	_	_	_	_
12-28	1678-1684	nearly	quantity[84]	new[84]	_	_
12-29	1685-1689	four	quantity[84]	new[84]	_	_
12-30	1690-1695	miles	quantity[84]	new[84]	_	_
12-31	1696-1697	)	_	_	_	_
12-32	1698-1705	without	_	_	_	_
12-33	1706-1714	stopping	_	_	_	_
12-34	1715-1716	.	_	_	_	_

#Text=The average treadmill time for strenuous exercise on a 25-degree incline is 31.9 minutes , well in excess of the 19 minute average of unmodified mice .
13-1	1717-1720	The	time[86]	new[86]	coref	13-13[89_86]
13-2	1721-1728	average	time[86]	new[86]	_	_
13-3	1729-1738	treadmill	place|time[86]	new|new[86]	_	_
13-4	1739-1743	time	time[86]	new[86]	_	_
13-5	1744-1747	for	time[86]	new[86]	_	_
13-6	1748-1757	strenuous	time[86]|abstract[87]	new[86]|new[87]	_	_
13-7	1758-1766	exercise	time[86]|abstract[87]	new[86]|new[87]	_	_
13-8	1767-1769	on	time[86]|abstract[87]	new[86]|new[87]	_	_
13-9	1770-1771	a	time[86]|abstract[87]|quantity[88]	new[86]|new[87]|new[88]	_	_
13-10	1772-1781	25-degree	time[86]|abstract[87]|quantity[88]	new[86]|new[87]|new[88]	_	_
13-11	1782-1789	incline	time[86]|abstract[87]|quantity[88]	new[86]|new[87]|new[88]	_	_
13-12	1790-1792	is	_	_	_	_
13-13	1793-1797	31.9	time[89]	giv[89]	coref	19-4[128_89]
13-14	1798-1805	minutes	time[89]	giv[89]	_	_
13-15	1806-1807	,	time[89]	giv[89]	_	_
13-16	1808-1812	well	time[89]	giv[89]	_	_
13-17	1813-1815	in	time[89]	giv[89]	_	_
13-18	1816-1822	excess	time[89]|abstract[90]	giv[89]|new[90]	_	_
13-19	1823-1825	of	time[89]|abstract[90]	giv[89]|new[90]	_	_
13-20	1826-1829	the	time[89]|abstract[90]|quantity[92]	giv[89]|new[90]|new[92]	_	_
13-21	1830-1832	19	time[89]|abstract[90]|quantity[92]	giv[89]|new[90]|new[92]	_	_
13-22	1833-1839	minute	time[89]|abstract[90]|time|quantity[92]	giv[89]|new[90]|giv|new[92]	_	_
13-23	1840-1847	average	time[89]|abstract[90]|quantity[92]	giv[89]|new[90]|new[92]	_	_
13-24	1848-1850	of	time[89]|abstract[90]|quantity[92]	giv[89]|new[90]|new[92]	_	_
13-25	1851-1861	unmodified	time[89]|abstract[90]|quantity[92]|animal[93]	giv[89]|new[90]|new[92]|giv[93]	coref	14-14[98_93]
13-26	1862-1866	mice	time[89]|abstract[90]|quantity[92]|animal[93]	giv[89]|new[90]|new[92]|giv[93]	_	_
13-27	1867-1868	.	_	_	_	_

#Text=Females can breed at two and a half years of age , whereas most female mice cannot breed after the first year .
14-1	1869-1876	Females	person	new	_	_
14-2	1877-1880	can	_	_	_	_
14-3	1881-1886	breed	_	_	_	_
14-4	1887-1889	at	_	_	_	_
14-5	1890-1893	two	abstract	new	_	_
14-6	1894-1897	and	_	_	_	_
14-7	1898-1899	a	time[96]	new[96]	_	_
14-8	1900-1904	half	time[96]	new[96]	_	_
14-9	1905-1910	years	time[96]	new[96]	_	_
14-10	1911-1913	of	time[96]	new[96]	_	_
14-11	1914-1917	age	time[96]|abstract	new[96]|new	_	_
14-12	1918-1919	,	_	_	_	_
14-13	1920-1927	whereas	_	_	_	_
14-14	1928-1932	most	animal[98]	giv[98]	coref	15-4[101_98]
14-15	1933-1939	female	animal[98]	giv[98]	_	_
14-16	1940-1944	mice	animal[98]	giv[98]	_	_
14-17	1945-1951	cannot	_	_	_	_
14-18	1952-1957	breed	_	_	_	_
14-19	1958-1963	after	_	_	_	_
14-20	1964-1967	the	time[99]	new[99]	_	_
14-21	1968-1973	first	time[99]	new[99]	_	_
14-22	1974-1978	year	time[99]	new[99]	_	_
14-23	1979-1980	.	_	_	_	_

#Text=A colony of 500 mice has been bred , starting from six independent germline transformations ( " founder " mice ) .
15-1	1981-1982	A	place[100]	new[100]	_	_
15-2	1983-1989	colony	place[100]	new[100]	_	_
15-3	1990-1992	of	place[100]	new[100]	_	_
15-4	1993-1996	500	place[100]|animal[101]	new[100]|giv[101]	appos	15-20[0_101]
15-5	1997-2001	mice	place[100]|animal[101]	new[100]|giv[101]	_	_
15-6	2002-2005	has	_	_	_	_
15-7	2006-2010	been	_	_	_	_
15-8	2011-2015	bred	_	_	_	_
15-9	2016-2017	,	_	_	_	_
15-10	2018-2026	starting	_	_	_	_
15-11	2027-2031	from	_	_	_	_
15-12	2032-2035	six	event[103]	new[103]	_	_
15-13	2036-2047	independent	event[103]	new[103]	_	_
15-14	2048-2056	germline	abstract|event[103]	new|new[103]	_	_
15-15	2057-2072	transformations	event[103]	new[103]	_	_
15-16	2073-2074	(	_	_	_	_
15-17	2075-2076	"	_	_	_	_
15-18	2077-2084	founder	person	new	_	_
15-19	2085-2086	"	_	_	_	_
15-20	2087-2091	mice	animal	giv	coref	16-20[113_0]
15-21	2092-2093	)	_	_	_	_
15-22	2094-2095	.	_	_	_	_

#Text=The level of PEPCK-C in muscle is 9 units per gram of muscle as opposed to only 0.08 in normal mice .
16-1	2096-2099	The	organization[106]	new[106]	coref	16-8[109_106]
16-2	2100-2105	level	organization[106]	new[106]	_	_
16-3	2106-2108	of	organization[106]	new[106]	_	_
16-4	2109-2116	PEPCK-C	organization[106]|person[107]	new[106]|giv[107]	_	_
16-5	2117-2119	in	organization[106]|person[107]	new[106]|giv[107]	_	_
16-6	2120-2126	muscle	organization[106]|person[107]|object	new[106]|giv[107]|giv	coref	16-13
16-7	2127-2129	is	_	_	_	_
16-8	2130-2131	9	organization[109]	giv[109]	_	_
16-9	2132-2137	units	organization[109]	giv[109]	_	_
16-10	2138-2141	per	organization[109]	giv[109]	_	_
16-11	2142-2146	gram	organization[109]|object[110]	giv[109]|new[110]	_	_
16-12	2147-2149	of	organization[109]|object[110]	giv[109]|new[110]	_	_
16-13	2150-2156	muscle	organization[109]|object[110]|object	giv[109]|new[110]|giv	coref	20-16
16-14	2157-2159	as	_	_	_	_
16-15	2160-2167	opposed	_	_	_	_
16-16	2168-2170	to	_	_	_	_
16-17	2171-2175	only	quantity[112]	new[112]	_	_
16-18	2176-2180	0.08	quantity[112]	new[112]	_	_
16-19	2181-2183	in	_	_	_	_
16-20	2184-2190	normal	animal[113]	giv[113]	coref	20-12[136_113]
16-21	2191-2195	mice	animal[113]	giv[113]	_	_
16-22	2196-2197	.	_	_	_	_

#Text=Levels of triglycerides and the number of mitochondria are also increased .
17-1	2198-2204	Levels	abstract[114]	new[114]	_	_
17-2	2205-2207	of	abstract[114]	new[114]	_	_
17-3	2208-2221	triglycerides	abstract[114]|substance	new[114]|new	_	_
17-4	2222-2225	and	abstract[114]	new[114]	_	_
17-5	2226-2229	the	abstract[114]|quantity[116]	new[114]|new[116]	_	_
17-6	2230-2236	number	abstract[114]|quantity[116]	new[114]|new[116]	_	_
17-7	2237-2239	of	abstract[114]|quantity[116]	new[114]|new[116]	_	_
17-8	2240-2252	mitochondria	abstract[114]|quantity[116]|object	new[114]|new[116]|new	_	_
17-9	2253-2256	are	_	_	_	_
17-10	2257-2261	also	_	_	_	_
17-11	2262-2271	increased	_	_	_	_
17-12	2272-2273	.	_	_	_	_

#Text=Hanson said that he did not expect that the results would be applicable to humans due to both practical and ethical considerations in addition to the fact that the genes might not function the same way in humans .
18-1	2274-2280	Hanson	person	giv	ana	18-4
18-2	2281-2285	said	_	_	_	_
18-3	2286-2290	that	_	_	_	_
18-4	2291-2293	he	person	giv	_	_
18-5	2294-2297	did	_	_	_	_
18-6	2298-2301	not	_	_	_	_
18-7	2302-2308	expect	_	_	_	_
18-8	2309-2313	that	_	_	_	_
18-9	2314-2317	the	abstract[120]	giv[120]	_	_
18-10	2318-2325	results	abstract[120]	giv[120]	_	_
18-11	2326-2331	would	_	_	_	_
18-12	2332-2334	be	_	_	_	_
18-13	2335-2345	applicable	_	_	_	_
18-14	2346-2348	to	_	_	_	_
18-15	2349-2355	humans	person[121]	new[121]	coref	18-38[0_121]
18-16	2356-2359	due	person[121]	new[121]	_	_
18-17	2360-2362	to	_	_	_	_
18-18	2363-2367	both	abstract[122]	new[122]	_	_
18-19	2368-2377	practical	abstract[122]	new[122]	_	_
18-20	2378-2381	and	abstract[122]	new[122]	_	_
18-21	2382-2389	ethical	abstract[122]	new[122]	_	_
18-22	2390-2404	considerations	abstract[122]	new[122]	_	_
18-23	2405-2407	in	abstract[122]	new[122]	_	_
18-24	2408-2416	addition	abstract[122]	new[122]	_	_
18-25	2417-2419	to	abstract[122]	new[122]	_	_
18-26	2420-2423	the	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-27	2424-2428	fact	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-28	2429-2433	that	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-29	2434-2437	the	abstract[122]|abstract[123]|abstract[124]	new[122]|new[123]|new[124]	_	_
18-30	2438-2443	genes	abstract[122]|abstract[123]|abstract[124]	new[122]|new[123]|new[124]	_	_
18-31	2444-2449	might	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-32	2450-2453	not	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-33	2454-2462	function	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-34	2463-2466	the	abstract[122]|abstract[123]|abstract[125]	new[122]|new[123]|new[125]	ana	19-1[0_125]
18-35	2467-2471	same	abstract[122]|abstract[123]|abstract[125]	new[122]|new[123]|new[125]	_	_
18-36	2472-2475	way	abstract[122]|abstract[123]|abstract[125]	new[122]|new[123]|new[125]	_	_
18-37	2476-2478	in	_	_	_	_
18-38	2479-2485	humans	person	giv	_	_
18-39	2486-2487	.	_	_	_	_

#Text=This is not the first time that the press has dubbed a genetically modified mouse a " mighty mouse " .
19-1	2488-2492	This	abstract	giv	_	_
19-2	2493-2495	is	_	_	_	_
19-3	2496-2499	not	_	_	_	_
19-4	2500-2503	the	time[128]	giv[128]	_	_
19-5	2504-2509	first	time[128]	giv[128]	_	_
19-6	2510-2514	time	time[128]	giv[128]	_	_
19-7	2515-2519	that	_	_	_	_
19-8	2520-2523	the	organization[129]	giv[129]	_	_
19-9	2524-2529	press	organization[129]	giv[129]	_	_
19-10	2530-2533	has	_	_	_	_
19-11	2534-2540	dubbed	_	_	_	_
19-12	2541-2542	a	animal[130]	giv[130]	appos	19-16[131_130]
19-13	2543-2554	genetically	animal[130]	giv[130]	_	_
19-14	2555-2563	modified	animal[130]	giv[130]	_	_
19-15	2564-2569	mouse	animal[130]	giv[130]	_	_
19-16	2570-2571	a	animal[131]	giv[131]	_	_
19-17	2572-2573	"	animal[131]	giv[131]	_	_
19-18	2574-2580	mighty	animal[131]	giv[131]	_	_
19-19	2581-2586	mouse	animal[131]	giv[131]	_	_
19-20	2587-2588	"	animal[131]	giv[131]	_	_
19-21	2589-2590	.	_	_	_	_

#Text=Earlier scientists at John Hopkins University announced that they had made mice with massively increased muscle mass that were larger and stronger than their normal cousins .
20-1	2591-2598	Earlier	person[132]	new[132]	ana	20-9[0_132]
20-2	2599-2609	scientists	person[132]	new[132]	_	_
20-3	2610-2612	at	person[132]	new[132]	_	_
20-4	2613-2617	John	person[132]|person[133]|organization[134]	new[132]|new[133]|giv[134]	_	_
20-5	2618-2625	Hopkins	person[132]|person[133]|organization[134]	new[132]|new[133]|giv[134]	_	_
20-6	2626-2636	University	person[132]|organization[134]	new[132]|giv[134]	_	_
20-7	2637-2646	announced	_	_	_	_
20-8	2647-2651	that	_	_	_	_
20-9	2652-2656	they	person	giv	ana	20-24
20-10	2657-2660	had	_	_	_	_
20-11	2661-2665	made	_	_	_	_
20-12	2666-2670	mice	animal[136]	giv[136]	coref	21-31[152_136]
20-13	2671-2675	with	animal[136]	giv[136]	_	_
20-14	2676-2685	massively	animal[136]|abstract[138]	giv[136]|new[138]	_	_
20-15	2686-2695	increased	animal[136]|abstract[138]	giv[136]|new[138]	_	_
20-16	2696-2702	muscle	animal[136]|object|abstract[138]	giv[136]|giv|new[138]	_	_
20-17	2703-2707	mass	animal[136]|abstract[138]	giv[136]|new[138]	_	_
20-18	2708-2712	that	_	_	_	_
20-19	2713-2717	were	_	_	_	_
20-20	2718-2724	larger	_	_	_	_
20-21	2725-2728	and	_	_	_	_
20-22	2729-2737	stronger	_	_	_	_
20-23	2738-2742	than	_	_	_	_
20-24	2743-2748	their	person|object[140]	giv|new[140]	_	_
20-25	2749-2755	normal	object[140]	new[140]	_	_
20-26	2756-2763	cousins	object[140]	new[140]	_	_
20-27	2764-2765	.	_	_	_	_

#Text=These alterations increased strength rather than endurance through the genetic modification of myostatin and follistatin , or by injection of a soluble form of ACVR2B to block myostatin activity in normal mice .
21-1	2766-2771	These	abstract[141]	new[141]	_	_
21-2	2772-2783	alterations	abstract[141]	new[141]	_	_
21-3	2784-2793	increased	_	_	_	_
21-4	2794-2802	strength	abstract[142]	new[142]	_	_
21-5	2803-2809	rather	abstract[142]	new[142]	_	_
21-6	2810-2814	than	abstract[142]	new[142]	_	_
21-7	2815-2824	endurance	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
21-8	2825-2832	through	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
21-9	2833-2836	the	abstract[142]|abstract[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
21-10	2837-2844	genetic	abstract[142]|abstract[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
21-11	2845-2857	modification	abstract[142]|abstract[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
21-12	2858-2860	of	abstract[142]|abstract[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
21-13	2861-2870	myostatin	abstract[142]|abstract[143]|abstract[144]|object	new[142]|giv[143]|new[144]|new	coref	21-28
21-14	2871-2874	and	abstract[142]|abstract[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
21-15	2875-2886	follistatin	abstract[142]|abstract[143]|abstract[144]|substance	new[142]|giv[143]|new[144]|new	_	_
21-16	2887-2888	,	_	_	_	_
21-17	2889-2891	or	_	_	_	_
21-18	2892-2894	by	_	_	_	_
21-19	2895-2904	injection	event[147]	new[147]	_	_
21-20	2905-2907	of	event[147]	new[147]	_	_
21-21	2908-2909	a	event[147]|substance[148]	new[147]|new[148]	_	_
21-22	2910-2917	soluble	event[147]|substance[148]	new[147]|new[148]	_	_
21-23	2918-2922	form	event[147]|substance[148]	new[147]|new[148]	_	_
21-24	2923-2925	of	event[147]|substance[148]	new[147]|new[148]	_	_
21-25	2926-2932	ACVR2B	event[147]|substance[148]|object	new[147]|new[148]|new	_	_
21-26	2933-2935	to	_	_	_	_
21-27	2936-2941	block	_	_	_	_
21-28	2942-2951	myostatin	object|abstract[151]	giv|giv[151]	_	_
21-29	2952-2960	activity	abstract[151]	giv[151]	_	_
21-30	2961-2963	in	_	_	_	_
21-31	2964-2970	normal	animal[152]	giv[152]	_	_
21-32	2971-2975	mice	animal[152]	giv[152]	_	_
21-33	2976-2977	.	_	_	_	_
